369 related articles for article (PubMed ID: 33451910)
41. Patients with inflammatory bowel disease on immunosuppressive drugs: perspectives' on COVID-19 and health care service during the pandemic.
Moum KM; Moum B; Opheim R
Scand J Gastroenterol; 2021 May; 56(5):545-551. PubMed ID: 33771086
[TBL] [Abstract][Full Text] [Related]
42. Baseline Disease Activity and Steroid Therapy Stratify Risk of COVID-19 in Patients With Inflammatory Bowel Disease.
Lukin DJ; Kumar A; Hajifathalian K; Sharaiha RZ; Scherl EJ; Longman RS; ;
Gastroenterology; 2020 Oct; 159(4):1541-1544.e2. PubMed ID: 32479824
[No Abstract] [Full Text] [Related]
43. Fatigue in inflammatory bowel diseases: relationship with age and disease activity.
Pellino G; Sciaudone G; Caserta V; Candilio G; De Fatico GS; Gagliardi S; Landino I; Patturelli M; Riegler G; Di Caprio EL; Canonico S; Gritti P; Selvaggi F
Int J Surg; 2014; 12 Suppl 2():S60-S63. PubMed ID: 25159230
[TBL] [Abstract][Full Text] [Related]
44. Disease Characteristics and Severity in Patients With Inflammatory Bowel Disease With Coexistent Diabetes Mellitus.
Din H; Anderson AJ; Ramos Rivers C; Proksell S; Koutroumpakis F; Salim T; Babichenko D; Tang G; Koutroubakis IE; Schwartz M; Johnston E; Barrie A; Harrison J; Hashash J; Dunn MA; Hartman DJ; Binion DG
Inflamm Bowel Dis; 2020 Aug; 26(9):1436-1442. PubMed ID: 31944255
[TBL] [Abstract][Full Text] [Related]
45. Physician Practice Patterns in Holding Inflammatory Bowel Disease Medications due to COVID-19, in the SECURE-IBD Registry.
Agrawal M; Brenner EJ; Zhang X; Colombel JF; Kappelman MD; Ungaro RC; ; Gearry RB; Kalpan GG; Kissous-Hunt M; Lewis JD; Ng SC; Rahier JF; Reinisch W; Ruemmele FM; Steinwurz F; Underwood FE
J Crohns Colitis; 2021 May; 15(5):860-863. PubMed ID: 33232456
[TBL] [Abstract][Full Text] [Related]
46. [Inflammatory bowel disease: experience of two Chilean centers].
Figueroa C C; Quera P R; Valenzuela E J; Jensen B C
Rev Med Chil; 2005 Nov; 133(11):1295-304. PubMed ID: 16446852
[TBL] [Abstract][Full Text] [Related]
47. The Impact of Vedolizumab on COVID-19 Outcomes Among Adult IBD Patients in the SECURE-IBD Registry.
Agrawal M; Zhang X; Brenner EJ; Ungaro RC; Kappelman MD; Colombel JF
J Crohns Colitis; 2021 Nov; 15(11):1877-1884. PubMed ID: 33884425
[TBL] [Abstract][Full Text] [Related]
48. Primary sclerosing cholangitis associated with inflammatory bowel disease: an observational study in a Southern Europe population focusing on new therapeutic options.
Franceschet I; Cazzagon N; Del Ross T; D'Incà R; Buja A; Floreani A
Eur J Gastroenterol Hepatol; 2016 May; 28(5):508-13. PubMed ID: 26872110
[TBL] [Abstract][Full Text] [Related]
49. Multi-Center Experience of Vedolizumab Effectiveness in Pediatric Inflammatory Bowel Disease.
Singh N; Rabizadeh S; Jossen J; Pittman N; Check M; Hashemi G; Phan BL; Hyams JS; Dubinsky MC
Inflamm Bowel Dis; 2016 Sep; 22(9):2121-6. PubMed ID: 27542130
[TBL] [Abstract][Full Text] [Related]
50. Impact of vedolizumab therapy on extra-intestinal manifestations in patients with inflammatory bowel disease: a multicentre cohort study nested in the OBSERV-IBD cohort.
Tadbiri S; Peyrin-Biroulet L; Serrero M; Filippi J; Pariente B; Roblin X; Buisson A; Stefanescu C; Trang-Poisson C; Altwegg R; Marteau P; Vaysse T; Bourrier A; Nancey S; Laharie D; Allez M; Savoye G; Gilletta C; Gagniere C; Vuitton L; Viennot S; Aubourg A; Pelletier AL; Bouguen G; Abitbol V; Fumery M; Claudepierre P; Bouhnik Y; Amiot A;
Aliment Pharmacol Ther; 2018 Feb; 47(4):485-493. PubMed ID: 29250803
[TBL] [Abstract][Full Text] [Related]
51. A four-decade analysis of the incidence trends, sociodemographic and clinical characteristics of inflammatory bowel disease patients at single tertiary centre, Kuala Lumpur, Malaysia.
Mokhtar NM; Nawawi KNM; Verasingam J; Zhiqin W; Sagap I; Azman ZAM; Mazlan L; Hamid HA; Yaacob NY; Rose IM; Den ELN; Wan MS; Raja Ali RA
BMC Public Health; 2019 Jun; 19(Suppl 4):550. PubMed ID: 31196184
[TBL] [Abstract][Full Text] [Related]
52. Incidence, Paris classification, and follow-up in a nationwide incident cohort of pediatric patients with inflammatory bowel disease.
Müller KE; Lakatos PL; Arató A; Kovács JB; Várkonyi Á; Szűcs D; Szakos E; Sólyom E; Kovács M; Polgár M; Nemes É; Guthy I; Tokodi I; Tóth G; Horváth Á; Tárnok A; Csoszánszki N; Balogh M; Vass N; Bódi P; Dezsőfi A; Gárdos L; Micskey E; Papp M; Cseh Á; Szabó D; Vörös P; Veres G;
J Pediatr Gastroenterol Nutr; 2013 Nov; 57(5):576-82. PubMed ID: 23820399
[TBL] [Abstract][Full Text] [Related]
53. How to manage inflammatory bowel disease during the COVID-19 pandemic: A guide for the practicing clinician.
Chebli JMF; Queiroz NSF; Damião AOMC; Chebli LA; Costa MHM; Parra RS
World J Gastroenterol; 2021 Mar; 27(11):1022-1042. PubMed ID: 33776370
[TBL] [Abstract][Full Text] [Related]
54. Short and long-term effectiveness and safety of vedolizumab in inflammatory bowel disease: results from the ENEIDA registry.
Chaparro M; Garre A; Ricart E; Iborra M; Mesonero F; Vera I; Riestra S; García-Sánchez V; Luisa De Castro M; Martin-Cardona A; Aldeguer X; Mínguez M; de-Acosta MB; Rivero M; Muñoz F; Andreu M; Bargalló A; González-Muñoza C; Pérez Calle JL; García-Sepulcre MF; Bermejo F; Huguet JM; Cabriada JL; Gutiérrez A; Mañosa M; Villoria A; Carbajo AY; Lorente R; García-López S; Piqueras M; Hinojosa E; Arajol C; Sicilia B; Conesa AM; Sainz E; Almela P; Llaó J; Roncero O; Camo P; Taxonera C; Domselaar MV; Pajares R; Legido J; Madrigal R; Lucendo AJ; Alcaín G; Doménech E; Gisbert JP;
Aliment Pharmacol Ther; 2018 Oct; 48(8):839-851. PubMed ID: 30281832
[TBL] [Abstract][Full Text] [Related]
55. Articular manifestations in patients with inflammatory bowel disease treated with vedolizumab.
Dupré A; Collins M; Nocturne G; Carbonnel F; Mariette X; Seror R
Rheumatology (Oxford); 2020 Nov; 59(11):3275-3283. PubMed ID: 32259251
[TBL] [Abstract][Full Text] [Related]
56. Lower incidence of COVID-19 in patients with inflammatory bowel disease treated with non-gut selective biologic therapy.
Ardizzone S; Ferretti F; Monico MC; Carvalhas Gabrielli AM; Carmagnola S; Bezzio C; Saibeni S; Bosani M; Caprioli F; Mazza S; Casini V; Cortelezzi CC; Parravicini M; Cassinotti A; Cosimo P; Indriolo A; Di Sabatino A; Lenti MV; Pastorelli L; Conforti F; Ricci C; Sarzi-Puttini P; Vecchi M; Maconi G
J Gastroenterol Hepatol; 2021 Nov; 36(11):3050-3055. PubMed ID: 34159648
[TBL] [Abstract][Full Text] [Related]
57. Burden of disease and increasing prevalence of inflammatory bowel disease in a population-based cohort in the Netherlands.
de Groof EJ; Rossen NG; van Rhijn BD; Karregat EP; Boonstra K; Hageman I; Bennebroek Evertsz F; Kingma PJ; Naber AH; van den Brande JH; Mallant-Hent RC; Mundt MW; D'Haens GR; Ponsioen CY
Eur J Gastroenterol Hepatol; 2016 Sep; 28(9):1065-72. PubMed ID: 27281507
[TBL] [Abstract][Full Text] [Related]
58. A Seroprevalence Study of Anti-SARS-CoV-2 Antibodies in Patients with Inflammatory Bowel Disease during the Second Wave of the COVID-19 Pandemic in Italy.
Di Ruscio M; Lunardi G; Buonfrate D; Gobbi F; Bertoli G; Piccoli D; Conti A; Geccherle A; Variola A
Medicina (Kaunas); 2021 Oct; 57(10):. PubMed ID: 34684085
[No Abstract] [Full Text] [Related]
59. Long-term efficacy and safety of vedolizumab in patients with inflammatory bowel diseases: A real-life experience from a tertiary referral center.
Dragoni G; Bagnoli S; Le Grazie M; Campani C; Rogai F; Manetti N; Bensi C; Macrì G; Galli A; Milla M
J Dig Dis; 2019 May; 20(5):235-242. PubMed ID: 30927309
[TBL] [Abstract][Full Text] [Related]
60. Drug insight: aminosalicylates for the treatment of IBD.
Nielsen OH; Munck LK
Nat Clin Pract Gastroenterol Hepatol; 2007 Mar; 4(3):160-70. PubMed ID: 17339853
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
